RNAi has finally been mentioned in a Nastech press release. They are spinning of the RNAi research into a subsidiary company called MDRNA. And the stock went up on this news!
While Nastech themselves had 5 years to create an RNAi drug, they are now claiming that the new company, MDRNA, will be seeking funding in the near future. Nastech screwed up the rest of their company so badly that they must now cut out RNAi research in order to survive. In the process they intend to send out their business people to ask for more money.
We here at the CCS would like to meet the people who intend to invest in MDRNA. We got a nice 
bridge we'd like to sell them.
bridge we'd like to sell them. 
No comments:
Post a Comment